Oral Iron Chelators
Oral Iron Chelators
复制标题
DOI：
10.1016/j.hoc.2009.11.001
复制
发表时间：
2010-02-01
影响因子：
2.4
通讯作者：
Kwiatkowski, Janet L.
中科院分区：
文献类型：
--
作者：
Kwiatkowski, Janet L.
有效的螯合治疗可以预防或逆转与铁过载相关的器官毒性，但心脏并发症和过早死亡仍在继续发生，主要与接受胃肠外治疗的患者的依从性困难有关。使用口服螯合剂可能能够克服这些困难，改善患者的预后。当定制个体螯合方案时，应考虑螯合剂在心脏和肝脏铁去除方面的功效和副作用概况。螯合治疗的更广泛选择，包括可能的联合治疗，应提高临床疗效和加强病人护理。
Effective chelation therapy can prevent or reverse organ toxicity related to iron overload, yet cardiac complications and premature death continue to occur, largely related to difficulties with compliance in patients who receive parenteral therapy. The use of oral chelators may be able to overcome these difficulties and improve patient outcomes. A chelator's efficacy at cardiac and liver iron removal and side-effect profile should be considered when tailoring individual chelation regimens. Broader options for chelation therapy, including possible combination therapy, should improve clinical efficacy and enhance patient care.